Cantor Fitzgerald Weighs in on CG Oncology FY2026 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for CG Oncology in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($3.58) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $75.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

A number of other equities research analysts also recently weighed in on CGON. JPMorgan Chase & Co. initiated coverage on CG Oncology in a report on Friday, May 2nd. They issued an “overweight” rating and a $41.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Monday, April 28th. Royal Bank of Canada increased their target price on shares of CG Oncology from $66.00 to $68.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 29th. Scotiabank initiated coverage on CG Oncology in a research note on Wednesday, April 16th. They issued a “sector perform” rating and a $23.00 price objective for the company. Finally, Morgan Stanley cut their target price on CG Oncology from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Monday, May 19th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, CG Oncology presently has an average rating of “Buy” and a consensus target price of $58.22.

CG Oncology Stock Up 1.8%

CGON opened at $27.48 on Wednesday. The company has a fifty day moving average of $23.46 and a 200-day moving average of $26.99. CG Oncology has a twelve month low of $14.80 and a twelve month high of $40.47. The stock has a market cap of $2.09 billion, a PE ratio of -18.20 and a beta of 0.86.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.09). The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.53 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in CG Oncology by 15.3% in the fourth quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company’s stock valued at $168,096,000 after purchasing an additional 779,730 shares during the last quarter. Barclays PLC raised its stake in shares of CG Oncology by 331.1% in the third quarter. Barclays PLC now owns 90,520 shares of the company’s stock valued at $3,416,000 after buying an additional 69,523 shares during the period. New York State Common Retirement Fund lifted its position in shares of CG Oncology by 16.7% during the 4th quarter. New York State Common Retirement Fund now owns 13,996 shares of the company’s stock valued at $401,000 after buying an additional 2,000 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of CG Oncology by 45.3% during the 4th quarter. Wells Fargo & Company MN now owns 28,234 shares of the company’s stock worth $810,000 after acquiring an additional 8,803 shares during the period. Finally, Swiss National Bank increased its holdings in CG Oncology by 144.2% in the 4th quarter. Swiss National Bank now owns 79,600 shares of the company’s stock worth $2,283,000 after acquiring an additional 47,000 shares during the last quarter. 26.56% of the stock is owned by institutional investors.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.40% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.